Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCY-M11 in platinum-resistant ovarian cancer and mesothelioma
NCT03608618Phase 1Terminated
- Sponsor
- MaxCyte
- Start
- Aug 2018
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of MCY-M11 in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC) and 1 more (7 cohorts), sponsored by MaxCyte. Primary endpoint: Incidence and severity of adverse events at 6 weeks. Started Aug 2018; status: terminated.
02
Drugs
MCY-M11
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)peritoneal mesothelioma
Beyond the preview
Go deeper on NCT03608618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608618.